Per-Olof Berggren at the Karolinska Institute
Professor Per-Olof Berggren at the Karolinska Institute has developed a unique in vivo imaging approach to enable identification of novel drugable targets for diabetes treatment.
Sweden
Diabetes Research
2012
<p><strong>Over 450 million people have diabetes worldwide</strong> – and it’s growing rapidly. Treatment of type 2 diabetes and its severe complications primarily focuses on identifying novel, more specific drugable targets and, based on these, designing new drugs that can be applied for more effective pharmacological regimens.</p>
<p><strong>In type 1 diabetes</strong> the major problem is to improve the success rate of islet transplantation. Professor Berggren and his group aims firstly to understand regulation of islet cell function and survival in the living organism and secondly the extent to which experimental work in rodents reflects the human islet.</p>
<p><strong>They use the eye’s anterior chamber</strong> as a novel and superior transplantation site, with the cornea as a natural body window visualizing human islet cell biology in vivo, non-invasively, longitudinally at single cell resolution.</p>
<div class="carousel-item active"><img width="1320" height="1025" src="https://jonasandchristinaafjochnickfoundation.com/wp-content/uploads/2020/07/P-O-1.png" class="d-block w-100" alt="" srcset="https://jonasandchristinaafjochnickfoundation.com/wp-content/uploads/2020/07/P-O-1.png 1320w, https://jonasandchristinaafjochnickfoundation.com/wp-content/uploads/2020/07/P-O-1-300×233.png 300w, https://jonasandchristinaafjochnickfoundation.com/wp-content/uploads/2020/07/P-O-1-1024×795.png 1024w, https://jonasandchristinaafjochnickfoundation.com/wp-content/uploads/2020/07/P-O-1-768×596.png 768w" sizes="(max-width: 1320px) 100vw, 1320px" /><p class="carousel-jcajf-caption"></p></div>